The contraceptive is the use of a device, or drugs for preventing pregnancy, the transmission of sexually transmitted infections, and birth control & family planning. The Asia Pacific contraceptive market is estimated to grow from $XX billion in 2018 to $XX billion by 2027, at a CAGR of 7.67% during the forecasting years of 2019-2027.
The use of advanced contraceptive methods and emergency contraceptives method, especially for teenagers and increase in awareness regarding sexually transmitted infections (STIs), are the major factors responsible for the growth of the contraceptives market. The economies of China, India, Japan, South Korea, Australia and the remaining countries collectively forming the Rest of Asia Pacific are the major influencers of the APAC contraceptive market. For decades, female sterilization has been the most popular form of contraception in India, and it remains so today. It is one of the reasons why the country is expected to have the fastest growth rate by the end of the forecasting period.
Apothecus Pharmaceutical Corporation, Pfizer, Inc., Pregna, Reckitt Benckiser PLC, OCON Medical Ltd., Church & Dwight Co., Inc., Agile Therapeutics, Merck & Co., Inc., Mayer Laboratories, Inc., Okamoto Industries, Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Afaxys, Inc., Bayer AG, and Cooper Surgical Inc. are the major companies that are mentioned in the report.